| SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies S Hart, KC Goh, V Novotny-Diermayr, CY Hu, H Hentze, YC Tan, B Madan, ... Leukemia 25 (11), 1751-1759, 2011 | 208 | 2011 |
| Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14, 19-dioxa-5, 7, 26-triaza-tetracyclo [19.3. 1.1 (2, 6). 1 (8, 12)] heptacosa-1 (25), 2 (26), 3, 5, 8, 10, 12 (27 … AD William, ACH Lee, S Blanchard, A Poulsen, EL Teo, H Nagaraj, E Tan, ... Journal of medicinal chemistry 54 (13), 4638-4658, 2011 | 195 | 2011 |
| SIRT1 modulating compounds from high-throughput screening as anti-inflammatory and insulin-sensitizing agents VM Nayagam, X Wang, YC Tan, A Poulsen, KC Goh, T Ng, H Wang, ... SLAS Discovery 11 (8), 959-967, 2006 | 189 | 2006 |
| Targeting the central pocket in human transcription factor TEAD as a potential cancer therapeutic strategy AV Pobbati, X Han, AW Hung, S Weiguang, N Huda, GY Chen, CB Kang, ... Structure 23 (11), 2076-2086, 2015 | 175 | 2015 |
| Discovery of (2E)-3-{2-Butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an Orally Active Histone Deacetylase Inhibitor with a … H Wang, N Yu, D Chen, KCL Lee, PL Lye, JWW Chang, W Deng, MCY Ng, ... Journal of medicinal chemistry 54 (13), 4694-4720, 2011 | 100 | 2011 |
| Discovery of Kinase Spectrum Selective Macrocycle (16E)-14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9 … AD William, ACH Lee, KC Goh, S Blanchard, A Poulsen, EL Teo, ... Journal of medicinal chemistry 55 (1), 169-196, 2012 | 97 | 2012 |
| Design and synthesis of ligand efficient dual inhibitors of janus kinase (JAK) and histone deacetylase (HDAC) based on ruxolitinib and vorinostat L Yao, N Mustafa, EC Tan, A Poulsen, P Singh, MD Duong-Thi, JXT Lee, ... Journal of medicinal chemistry 60 (20), 8336-8357, 2017 | 89 | 2017 |
| Design and synthesis of janus kinase 2 (JAK2) and histone deacetlyase (HDAC) bispecific inhibitors based on pacritinib and evidence of dual pathway inhibition in hematological … EG Yang, N Mustafa, EC Tan, A Poulsen, PM Ramanujulu, WJ Chng, ... Journal of medicinal chemistry 59 (18), 8233-8262, 2016 | 87 | 2016 |
| Fragment-based ligand design of novel potent inhibitors of tankyrases EA Larsson, A Jansson, FM Ng, SW Then, R Panicker, B Liu, ... Journal of Medicinal Chemistry 56 (11), 4497-4508, 2013 | 83 | 2013 |
| Target mechanism-based whole-cell screening identifies bortezomib as an inhibitor of caseinolytic protease in mycobacteria W Moreira, GJY Ngan, JL Low, A Poulsen, BCS Chia, MJY Ang, A Yap, ... MBio 6 (3), 10.1128/mbio. 00253-15, 2015 | 71 | 2015 |
| Target mechanism-based whole-cell screening identifies bortezomib as an inhibitor of caseinolytic protease in mycobacteria W Moreira, GJY Ngan, JL Low, A Poulsen, BCS Chia, MJY Ang, A Yap, ... MBio 6 (3), 10.1128/mbio. 00253-15, 2015 | 71 | 2015 |
| Targeting cancer addiction for SALL4 by shifting its transcriptome with a pharmacologic peptide BH Liu, C Jobichen, CSB Chia, THM Chan, JP Tang, TXY Chung, J Li, ... Proceedings of the National Academy of Sciences 115 (30), E7119-E7128, 2018 | 56 | 2018 |
| Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 … A Poulsen, A William, S Blanchard, A Lee, H Nagaraj, H Wang, E Teo, ... Journal of computer-aided molecular design 26 (4), 437-450, 2012 | 52 | 2012 |
| Discovery of the Macrocycle (9E)-15-(2-(Pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17 … AD William, ACH Lee, A Poulsen, KC Goh, B Madan, S Hart, E Tan, ... Journal of medicinal chemistry 55 (6), 2623-2640, 2012 | 51 | 2012 |
| Combining the [2, 3] sigmatropic rearrangement and ring-closing metathesis strategies for the synthesis of spirocyclic alkaloids. A short and efficient route to … D Tanner, L Hagberg, A Poulsen Tetrahedron 55 (5), 1427-1440, 1999 | 50 | 1999 |
| Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependant kinases (CDKs … A Poulsen, A William, S Blanchard, H Nagaraj, M Williams, H Wang, ... Journal of molecular modeling 19, 119-130, 2013 | 47 | 2013 |
| Discovery and optimization of a porcupine inhibitor AJ Duraiswamy, MA Lee, B Madan, SH Ang, ESW Tan, WWV Cheong, ... Journal of medicinal chemistry 58 (15), 5889-5899, 2015 | 44 | 2015 |
| Strategic design of catalytic lysine‐targeting reversible covalent BCR‐ABL inhibitors D Quach, G Tang, J Anantharajan, N Baburajendran, A Poulsen, JLK Wee, ... Angewandte Chemie 133 (31), 17268-17274, 2021 | 42 | 2021 |
| Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat Y Chu-Farseeva, N Mustafa, A Poulsen, EC Tan, JJY Yen, WJ Chng, ... European journal of medicinal chemistry 158, 593-619, 2018 | 40 | 2018 |
| Optimization of selective mitogen-activated protein kinase interacting kinases 1 and 2 inhibitors for the treatment of blast crisis leukemia H Yang, LR Chennamaneni, MWT Ho, SH Ang, ESW Tan, DA Jeyaraj, ... Journal of Medicinal Chemistry 61 (10), 4348-4369, 2018 | 40 | 2018 |
